Tucatinib usually requires long-term use, and the specific medication cycle depends on the disease progression and patient tolerance. It generally lasts until the disease worsens or intolerable toxicity occurs.

The necessity of long-term medication

(1) Maintaining therapeutic efficacy: As a targeted therapy drug, it is necessary to continuously inhibit the growth of HER2 positive tumor cells, and interruption may lead to disease recurrence.

(2) Clinical trial data: The median treatment time is about 8.6 months, and some patients require medication for more than 1 year.

2 factors affecting medication duration

(1) Disease response: Drug sensitivity can be maintained for a long time, and the plan needs to be adjusted after drug resistance.

(2) Adverse reactions: Severe liver toxicity or diarrhea may shorten the course of treatment.

(3) Combination therapy: When used in combination with trastuzumab, it should be maintained synchronously.

Long term medication management

(1) Regular assessment: Imaging examination every 8-12 weeks, liver function monitoring every 3 weeks.

(2) Dose adjustment: Implement reduction or suspension based on toxicity reaction grading.

4. Handling of Special Situations

(1) Liver dysfunction: Children Pugh grade C patients should be carefully evaluated for long-term medication risks.

(2) Fertility patients: Continuous contraceptive measures should be taken during the medication period.